RecruitingNot Applicable

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

United States, Germany, Netherlands400 participantsStarted 2023-01-01

Plain-language summary

This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Congenital heart defect. * Age ≥ 18 years. * Initiated on treatment with an SGLT2i. Exclusion Criteria: \- No consent for data collection.

What they're measuring

Prescription patterns

Timeframe: Baseline information.

Trial details

NCT IDNCT06932081

SponsorLeiden University Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12-31

Contact for this trial

Ralph M.L. Neijenhuis, MD

+31 71 5262020 r.m.l.neijenhuis@lumc.nl

View on ClinicalTrials.gov More Adult Congenital Heart Disease trials